Riskpilot← Back to searchSign inGet full accessDevopharma ApS
APSActiveCVR 38968254Strandvejen 301, 2.Research and experimental development on natural sciences and engineering · NACE 7210Est. 2017— employees
Revenue 2024
DKK -3K
0% vs 2023
EBITDA margin
100.0%
0% vs 2023
Equity ratio
28.1%
Financial strength
Net profit 2024
DKK -3K
0% vs 2023
| Revenue | DKK -3K | +0% |
| EBITDA | DKK -3K | +0% |
| Net profit | DKK -3K | +0% |
| Total assets | DKK 100K | +0% |
| Equity | DKK 28K | -10% |
| Employees | — | — |
Legal name
Devopharma ApS
CVR number
38968254
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
25. september 2017
Share capital
DKK 50.000
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af selskabets direktion
Company purpose
Selskabets formål er at udøve virksomhed med forskning og eksperimentel udvikling indenfor bioteknologi
Address
Strandvejen 301, 2.
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | -3 | -3 | -3 | -3 | -3 | -3 | -3 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -3 | -3 | -3 | -3 | -3 | -3 | -3 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -3 | -3 | -3 | -3 | -3 | -3 | -3 |
| Net financials | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -3 | -3 | -3 | -3 | -3 | -3 | -3 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | -3 | -3 | -3 | -3 | -3 | -3 | -3 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | 50 | 100 | 100 | 100 | 100 | 100 | 100 |
| Equity | 47 | 44 | 41 | 38 | 34 | 31 | 28 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 3 | 56 | 59 | 63 | 66 | 69 | 72 |
| Total debt | 3 | 56 | 59 | 63 | 66 | 69 | 72 |
EBITDA margin
-312500.0%
This company
15.8%
Market median
-1977948% vs market
20182024
Equity ratio
28.1%
This company
38.2%
Market median
-26% vs market
20182024
Return on equity
-11.1%
This company
18.4%
Market median
-160% vs market
20182024
Net profit margin
-312500.0%
This company
8.1%
Market median
-3858125% vs market
20182024
Asset turnover
-0.03×
This company
1.12×
Market median
-103% vs market
20182024
Debt / equity
2.56×
This company
0.62×
Market median
-313% vs market
20182024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2017-09-25 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AA Founder | Founder | 2017 | — | — |
HN Management | Management | 2017 | — | — |
SL Management | Management | 2017 | — | — |
MO Management | Management | 2017 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
HN HOLDING 2010 ApS | Company | 50.0% | 50.0% | 2017 |
Friendly Holding ApS | Company | 25.0% | 25.0% | 2017 |
JARCO HOLDING ApS | Company | 15.0% | 15.0% | 2026 |
GAIN ApS | Company | 10.0% | 10.0% | 2026 |
| Individual | 25.0% | 25.0% | 2019 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
JARCO HOLDING ApS
Devopharma ApS Board members of Devopharma ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Allan Anesteen Tharuman | Founder | 0 companies |
| Henrik Nakskov | Management | 0 companies |
| Søren Luplau-Pagh | Management | 0 companies |
| Morten Olesen | Management | 0 companies |